PDE5 Inhibitor | Film-coated tablets | B2B pharmaceutical enquiries
Kwiklis-10 Tablets: Each film-coated tablet contains Tadalafil 10 mg.
Tadalafil Tablets BP 20 mg: Each film-coated tablet contains Tadalafil BP 20 mg; excipients q.s.
Usage: Treatment of erectile dysfunction under medical supervision.
Therapeutic category: PDE5 inhibitor / Urological medicine.
SKU: Tadalafil Tablets
Categories: Pharmaceutical Exporter India · Pharmaceutical Formulations India · WHO GMP Certified Formulations
Tadalafil Tablets is listed for pharmaceutical business-to-business enquiries. Exact active ingredients, formulation, strength, pack configuration and manufacturer details should be confirmed against the product label and approved technical documentation before ordering.
Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction. The supplied product compositions confirm Kwiklis-10 (10 mg) and Tadalafil BP 20 mg film-coated tablets. Tadalafil may support erectile function when sexual stimulation occurs, and its effects may persist for up to 36 hours. Healthy Life Pharma Pvt. Ltd. and Healthy Inc are identified as manufacturer and exporter in the supplied material; site certifications and market authorizations should be verified before publication.
| Product | Tadalafil Tablets |
|---|---|
| Brand supplied | Kwiklis-10 (10 mg) |
| Confirmed strengths | 10 mg and 20 mg |
| Composition 10 mg | Tadalafil 10 mg per film-coated tablet |
| Composition 20 mg | Tadalafil BP 20 mg per film-coated tablet |
| Dosage form | Film-coated tablet |
| Therapeutic class | PDE5 inhibitor / Erectile dysfunction therapy |
| CAS number | 171596-29-5 |
| Other strengths | 2.5 mg and 5 mg mentioned as background only; not confirmed as supplied products |
| Packaging and shelf life | To be confirmed against approved product dossier |
Tadalafil has low aqueous solubility, so development of a consistent oral tablet may require attention to API particle-size distribution, blending uniformity, granulation strategy, dissolution, film-coating quality and packaging. The specific processes, equipment and excipients used for this product must be confirmed from its approved manufacturing record; micronization, surfactant use and named coating systems should not be assumed.
Applicable batch-release tests may include identity, assay, content uniformity, dissolution, related substances and physical tablet quality, in accordance with the registered specification and relevant pharmacopoeial standard. Numerical acceptance criteria, stability data and shelf life must be confirmed from approved product documents.
Erectile dysfunction: Tadalafil inhibits PDE5, helping preserve cGMP-mediated smooth-muscle relaxation and increase penile blood flow during sexual stimulation. It does not independently cause an erection and is not an aphrodisiac.
Other tadalafil formulations may be authorized for benign prostatic hyperplasia or pulmonary arterial hypertension in some markets, but these uses are not established for the supplied 10 mg and 20 mg product labels. Product-specific authorization must be checked.
B2B buyers may enquire about registration dossiers (CTD/ACTD, where available), certificate of analysis, manufacturing licence, GMP documentation, packaging options and market-specific export requirements. WHO-GMP, COPP, FSC, Star Export House status, destination approvals and shipping terms should be verified directly with the supplier.
Q: Which strengths are confirmed?
A: 10 mg film-coated tablets (Kwiklis-10) and 20 mg BP film-coated tablets.
Q: How long can tadalafil work?
A: Erectile-function effects may be possible for up to 36 hours; this does not mean a continuous erection.
Q: Can tadalafil be taken with nitrate medicines?
A: No. Combining tadalafil with nitrates or riociguat can cause dangerous hypotension.
Q: Is tadalafil identical to sildenafil?
A: Both are PDE5 inhibitors, but their onset, duration and prescribing details differ.
For erectile dysfunction, a commonly prescribed starting dose for on-demand tadalafil is 10 mg before anticipated sexual activity; a clinician may adjust it to 20 mg or reduce it based on response, tolerability and health conditions. Do not take more than once per day. It may be taken with or without food. Lower-dose daily regimens exist, but 2.5 mg and 5 mg products are not confirmed in this listing. Kidney or liver impairment and interacting medicines may require different dosing. Follow the locally approved label and prescriber instructions.
Common effects include headache, flushing, dyspepsia, nasal congestion, back pain and muscle aches. Never combine tadalafil with nitrates (including nitroglycerin) or riociguat because blood pressure can fall dangerously. Use caution with alpha-blockers, blood-pressure medicines, strong CYP3A4 inhibitors and heavy alcohol consumption. Seek urgent care for an erection lasting more than four hours, sudden vision or hearing loss, chest pain or severe dizziness. Cardiovascular fitness for sexual activity should be assessed by a clinician.
Store in the original pack, away from excess moisture and heat, according to the approved product label. The exact temperature limit and shelf life must be verified against the registered stability data. Keep out of reach of children.
For professional and B2B reference. Prescribing information, manufacturing claims, certification and market-specific approvals require verification.